Synthetic Biology: Immunotherapy by Design.

Cellular immunotherapy holds great promise for the treatment of human disease. Clinical evidence suggests that T cell immunotherapies have the potential to combat cancers that evade traditional immunotherapy. Despite promising results, adverse effects leading to fatalities have left scientists seeking tighter control over these therapies, which is reflected in the growing body of synthetic biology literature focused on developing tightly controlled, context-independent parts. In addition, researchers are adapting these tools for other uses, such as for the treatment of autoimmune disease, HIV infection, and fungal interactions. We review this body of work and devote special attention to approaches that may lend themselves to the development of an "ideal" therapy: one that is safe, efficient, and easy to manufacture. We conclude with a look toward the future of immunotherapy: how synthetic biology can shift the paradigm from the treatment of disease to a focus on wellness and human health as a whole.

[1]  T. Wang,et al.  Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer , 2017, Oncoimmunology.

[2]  Simon C Watkins,et al.  The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. , 2016, Immunity.

[3]  S. Rosenberg,et al.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity , 2015, Journal of Virology.

[4]  Wendell A. Lim,et al.  Bacterial Virulence Proteins as Tools to Rewire Kinase Pathways in Yeast and Immune Cells , 2012, Nature.

[5]  L. Bekker,et al.  Adjunctive interferon-&ggr; immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial , 2012, AIDS.

[6]  W. Meyer,et al.  Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. , 2012, Cytotherapy.

[7]  Kole T. Roybal,et al.  Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors , 2016, Cell.

[8]  Kole T. Roybal,et al.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.

[9]  B. Spellberg,et al.  Safety and efficacy of activated transfected killer cells for neutropenic fungal infections. , 2010, The Journal of infectious diseases.

[10]  Tatsuo Fukagawa,et al.  An auxin-based degron system for the rapid depletion of proteins in nonplant cells , 2009, Nature Methods.

[11]  Navneeta Bansal,et al.  Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies , 2012, Clinical Cancer Research.

[12]  M. Petrou,et al.  Exogenous Interferon‐γ Immunotherapy for Invasive Fungal Infections in Kidney Transplant Patients , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  C. Liu,et al.  Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses , 2010, Clinical Cancer Research.

[14]  A. Ohta,et al.  A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.

[15]  Kole T. Roybal,et al.  Synthetic biology approaches to engineer T cells. , 2015, Current opinion in immunology.

[16]  Y. Lévy,et al.  CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses , 2017, Nature.

[17]  A. Lanzavecchia,et al.  Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease , 2016, Science.

[18]  Matthew L Baker,et al.  TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy , 2013, Molecular therapy. Nucleic acids.

[19]  M. Levings,et al.  Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. , 2016, The Journal of clinical investigation.

[20]  Pamela A. Silver,et al.  Engineering synthetic TAL effectors with orthogonal target sites , 2012, Nucleic acids research.

[21]  Swapnil Bhatia,et al.  A single-layer platform for Boolean logic and arithmetic through DNA excision in mammalian cells , 2017, Nature Biotechnology.

[22]  R. Eils,et al.  Engineering light-inducible nuclear localization signals for precise spatiotemporal control of protein dynamics in living cells , 2014, Nature Communications.

[23]  D. Scott,et al.  FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. , 2017, Blood.

[24]  A. Scheffold,et al.  Clinical-scale isolation of the total Aspergillus fumigatus-reactive T-helper cell repertoire for adoptive transfer. , 2015, Cytotherapy.

[25]  Kensaku Mori,et al.  Advanced Endoscopic Navigation: Surgical Big Data, Methodology, and Applications. , 2018, Annual review of biomedical engineering.

[26]  L. E. Strong,et al.  Engineering Approaches to Study Cellular Decision Making. , 2018, Annual review of biomedical engineering.

[27]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[28]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[29]  A. Pezeshki,et al.  Naturally occurring p16Ink4a-positive cells shorten healthy lifespan , 2016, Nature.

[30]  Christopher M. Vockley,et al.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors , 2013, Nature Methods.

[31]  J. E. Brewer,et al.  NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma , 2015, Nature Medicine.

[32]  C. Gersbach,et al.  A light-inducible CRISPR/Cas9 system for control of endogenous gene activation , 2015, Nature chemical biology.

[33]  N. Mihaylova,et al.  Selective silencing of DNA‐specific B lymphocytes delays lupus activity in MRL/lpr mice , 2007, European journal of immunology.

[34]  J. Bonneterre,et al.  Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. , 2011, Cancer research.

[35]  L. Tsimring,et al.  Entrainment of a Population of Synthetic Genetic Oscillators , 2011, Science.

[36]  B. Ebert,et al.  Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[38]  J. Collins,et al.  Construction of a genetic toggle switch in Escherichia coli , 2000, Nature.

[39]  W. Lim,et al.  The Principles of Engineering Immune Cells to Treat Cancer , 2017, Cell.

[40]  E. Freireich,et al.  Impact of high‐dose granulocyte transfusions in patients with cancer with candidemia , 2004, Cancer.

[41]  B. Blazar,et al.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.

[42]  S. Gerber,et al.  Optogenetic control of chemokine receptor signal and T-cell migration , 2014, Proceedings of the National Academy of Sciences.

[43]  Christopher A. Voigt,et al.  Genetic circuit design automation , 2016, Science.

[44]  A. Zaas,et al.  Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease , 2009, Proceedings of the National Academy of Sciences.

[45]  Timothy S. Ham,et al.  Production of the antimalarial drug precursor artemisinic acid in engineered yeast , 2006, Nature.

[46]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[47]  Russell M. Gordley,et al.  Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors , 2016, Cell.

[48]  L. Coussens,et al.  Inflammation and Cancer , 2016 .

[49]  D. Gottlieb,et al.  Adoptive T-cell therapy for fungal infections in haematology patients , 2015, Clinical & translational immunology.

[50]  L. Serrano,et al.  Engineering stability in gene networks by autoregulation , 2000, Nature.

[51]  M. Elowitz,et al.  A synthetic oscillatory network of transcriptional regulators , 2000, Nature.

[52]  Dana Carroll,et al.  Enhancing Gene Targeting with Designed Zinc Finger Nucleases , 2003, Science.

[53]  E. Yannaki,et al.  Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: Progress and challenges. , 2016, Critical reviews in oncology/hematology.

[54]  Leonidas Bleris,et al.  Biological 2-Input Decoder Circuit in Human Cells , 2014, ACS synthetic biology.

[55]  C. Macken,et al.  A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  D. Powell,et al.  A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. , 2012, Cancer research.

[57]  Yu Cao,et al.  Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies , 2016, Proceedings of the National Academy of Sciences.

[58]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[59]  F. Lienert,et al.  Synthetic biology in mammalian cells: next generation research tools and therapeutics , 2014, Nature Reviews Molecular Cell Biology.

[60]  C. Barbas,et al.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.

[61]  Alimuddin Zumla,et al.  T-Cell Therapy: Options for Infectious Diseases , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Morgan L. Maeder,et al.  CRISPR RNA-guided activation of endogenous human genes , 2013, Nature Methods.

[64]  M. Sadelain,et al.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  M. Horton,et al.  Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor , 2012, Cancer Immunology, Immunotherapy.

[66]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[67]  Xiuyan Wang,et al.  Clinical manufacturing of CAR T cells: foundation of a promising therapy , 2016, Molecular therapy oncolytics.

[68]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[69]  H. Heslop,et al.  Reversal of tumor immune inhibition using a chimeric cytokine receptor. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[70]  Tyler Hill,et al.  Inclusion of Strep-Tag II in design of antigen receptors for T cell immunotherapy , 2016, Nature Biotechnology.

[71]  D. Clegg,et al.  HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells , 2017, Nature Biotechnology.

[72]  D. Scott,et al.  Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. , 2015, Blood.

[73]  Robert DeRose,et al.  Rapid and orthogonal logic gating with a gibberellin-induced dimerization system. , 2012, Nature chemical biology.

[74]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[75]  Zong-hai Li,et al.  Clinical application and research progress on chimeric antigen receptor-modified T cells , 2016 .

[76]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[77]  S. Riddell,et al.  Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. , 2007, Human gene therapy.

[78]  Ronnie J Winfrey,et al.  Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. , 2008, Molecular cell.

[79]  S. Rosenberg,et al.  Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy , 2012, Gene Therapy.

[80]  Tobias Meyer,et al.  An inducible translocation strategy to rapidly activate and inhibit small GTPase signaling pathways , 2005, Nature Methods.

[81]  Jing Sun,et al.  Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor , 2011, Clinical Cancer Research.

[82]  Zachary N. Russ,et al.  An enzyme-coupled biosensor enables (S)-reticuline production in yeast from glucose. , 2015, Nature chemical biology.

[83]  G. Barnea,et al.  The genetic design of signaling cascades to record receptor activation , 2008, Proceedings of the National Academy of Sciences.

[84]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[85]  E. V. Van Allen,et al.  Genomic correlates of response to immune checkpoint blockade , 2019, Nature Medicine.

[86]  James J. Collins,et al.  Using Targeted Chromatin Regulators to Engineer Combinatorial and Spatial Transcriptional Regulation , 2014, Cell.

[87]  T. Dull,et al.  Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. , 1994, Blood.

[88]  Brian Kuhlman,et al.  Engineering an improved light-induced dimer (iLID) for controlling the localization and activity of signaling proteins , 2014, Proceedings of the National Academy of Sciences.

[89]  Zhen Xie,et al.  Logic integration of mRNA signals by an RNAi-based molecular computer , 2010, Nucleic acids research.

[90]  Wendell A. Lim,et al.  Remote control of therapeutic T cells through a small molecule–gated chimeric receptor , 2015, Science.

[91]  Michel Sadelain,et al.  The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.

[92]  Mithat Gönen,et al.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.

[93]  Tongguang Wang,et al.  Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.

[94]  Ernst Weber,et al.  A Modular Cloning System for Standardized Assembly of Multigene Constructs , 2011, PloS one.

[95]  A. Tosti,et al.  Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. , 2005, Blood.

[96]  N. Sharpless,et al.  Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice , 2015, Nature Medicine.

[97]  F. Bushman,et al.  Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells , 2012, Science Translational Medicine.

[98]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[99]  Sadik H. Kassim,et al.  Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma , 2015, Clinical Cancer Research.

[100]  S. Forman,et al.  Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. , 2012, Molecular immunology.

[101]  Drew Endy,et al.  Amplifying Genetic Logic Gates , 2013, Science.

[102]  G. Drusano,et al.  Dose Range Evaluation of Mycograb C28Y Variant, a Human Recombinant Antibody Fragment to Heat Shock Protein 90, in Combination with Amphotericin B-Desoxycholate for Treatment of Murine Systemic Candidiasis , 2011, Antimicrobial Agents and Chemotherapy.

[103]  R. Schwendener,et al.  Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. , 2009, Cancer research.

[104]  E. Elinav,et al.  Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. , 2009, Gastroenterology.

[105]  S. Heilshorn,et al.  Engineering Hydrogel Microenvironments to Recapitulate the Stem Cell Niche. , 2018, Annual review of biomedical engineering.

[106]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[107]  A. Casadevall,et al.  Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. , 2010, The Journal of infectious diseases.

[108]  Y. Kew,et al.  Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[109]  Timothy K Lu,et al.  Synthetic circuits integrating logic and memory in living cells , 2013, Nature Biotechnology.

[110]  Sang Yup Lee,et al.  One-step fermentative production of poly(lactate-co-glycolate) from carbohydrates in Escherichia coli , 2016, Nature Biotechnology.

[111]  Chan Hyuk Kim,et al.  Versatile strategy for controlling the specificity and activity of engineered T cells , 2016, Proceedings of the National Academy of Sciences.

[112]  Christopher A. Voigt,et al.  Spatiotemporal Control of Cell Signalling Using A Light-Switchable Protein Interaction , 2009, Nature.

[113]  B. Zoltowski,et al.  Optimized second generation CRY2/CIB dimerizers and photoactivatable Cre recombinase , 2016, Nature chemical biology.

[114]  J. Wess,et al.  Engineering GPCR signaling pathways with RASSLs , 2008, Nature Methods.

[115]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[116]  C. Smolke,et al.  Complete biosynthesis of opioids in yeast , 2015, Science.

[117]  T. Harrison,et al.  Immunotherapy for fungal infections. , 2012, Current opinion in microbiology.

[118]  H. Heslop,et al.  An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.

[119]  Keith E. J. Tyo,et al.  Isoprenoid Pathway Optimization for Taxol Precursor Overproduction in Escherichia coli , 2010, Science.

[120]  Joshua N Leonard,et al.  Rewiring human cellular input-output using modular extracellular sensors. , 2017, Nature chemical biology.

[121]  O. Yang,et al.  HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies , 2016, Journal of Virology.

[122]  Jeffry D. Sander,et al.  Engineering Designer Transcription Activator‐‐Like Effector Nucleases (TALENs) by REAL or REAL‐Fast Assembly , 2012, Current protocols in molecular biology.

[123]  Michel Sadelain,et al.  PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses , 2013, Science Translational Medicine.

[124]  T. Wandless,et al.  Synthesis and analysis of stabilizing ligands for FKBP-derived destabilizing domains. , 2008, Bioorganic & Medicinal Chemistry Letters.

[125]  S. Bhatia,et al.  Ultrasensitive tumour-penetrating nanosensors of protease activity , 2017, Nature Biomedical Engineering.

[126]  Ahmad S. Khalil,et al.  A Synthetic Biology Framework for Programming Eukaryotic Transcription Functions , 2012, Cell.

[127]  A. Scharenberg,et al.  Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[128]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[129]  A. Burgard,et al.  Metabolic engineering of Escherichia coli for direct production of 1,4-butanediol. , 2011, Nature chemical biology.

[130]  J. Liao,et al.  Non-fermentative pathways for synthesis of branched-chain higher alcohols as biofuels , 2008, Nature.

[131]  Adrian J. Thrasher,et al.  Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells , 2017, Science Translational Medicine.

[132]  Michel Sadelain,et al.  Therapeutic T cell engineering , 2017, Nature.

[133]  Myles A Brown,et al.  Lac repressor can regulate expression from a hybrid SV40 early promoter containing a lac operator in animal cells , 1987, Cell.

[134]  Xu Zhang,et al.  Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy , 2016, Journal of Virology.

[135]  Eugene S. Kim,et al.  Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes , 2015, Nature Medicine.

[136]  James Chappell,et al.  Creating small transcription activating RNAs. , 2015, Nature chemical biology.

[137]  E. Burchielli,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 22, 2013. For personal use only. , 2002 .

[138]  Adrian P Gee,et al.  Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.

[139]  David D. Smith,et al.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.

[140]  C. C. Richardson,et al.  Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes , 2016, Diabetes.

[141]  O. Abudayyeh,et al.  Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease , 2012, Nature Biotechnology.

[142]  J. Roszik,et al.  Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection , 2014, Proceedings of the National Academy of Sciences.

[143]  J. Stelling,et al.  β-cell–mimetic designer cells provide closed-loop glycemic control , 2016, Science.

[144]  Michael Z. Lin,et al.  Tunable and reversible drug control of protein production via a self-excising degron , 2015, Nature chemical biology.

[145]  R. Weiss,et al.  A universal RNAi-based logic evaluator that operates in mammalian cells , 2007, Nature Biotechnology.

[146]  R. Holt,et al.  Cell-Based Therapeutics: Making a Faustian Pact with Biology. , 2017, Trends in molecular medicine.

[147]  Ron Weiss,et al.  Open-source, community-driven microfluidics with Metafluidics , 2017, Nature Biotechnology.

[148]  A. Katakam,et al.  Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity , 2009, Cancer Gene Therapy.

[149]  D. Kontoyiannis,et al.  The safety of interferon‐γ‐1b therapy for invasive fungal infections after hematopoietic stem cell transplantation , 2005 .

[150]  D. G. Gibson,et al.  Enzymatic assembly of DNA molecules up to several hundred kilobases , 2009, Nature Methods.

[151]  J. Ito,et al.  Epidemiology and treatment approaches in management of invasive fungal infections , 2011, Clinical epidemiology.

[152]  Jens Boch,et al.  Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factors , 2010, Proceedings of the National Academy of Sciences.

[153]  J. Collins,et al.  Toehold Switches: De-Novo-Designed Regulators of Gene Expression , 2014, Cell.

[154]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[155]  Ai Leen Ang,et al.  Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era – experience from an adult haematology unit in Singapore , 2011, Transfusion medicine.